ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Key Inclusion Criteria:

1. Male or female, age ≥65 years old or age >18 years old or <65 years old, age >18 yearsold or <65 years old shall meet any of the following criteria simultaneously:A.Disease accumulation score (CIRS) > 6;B. Creatinine clearance at 30-69 mL/ min (Cockcroft-Gault assessment)
2. Enhanced computed tomography/magnetic resonance imaging (CT/MRI) detection hadmeasurable lesions: at least one lymph node had a maximum axis of more than 1.5 cm andhad a measurable vertical dimension
3. ECOG physical strength score is 0-2.
4. Expected survival time >6 months.
5. Voluntary written informed consent prior to screening.

Key Exclusion Criteria:

1. Patients with stroke or intracranial hemorrhage in the first 6 months were randomlyassigned.
2. Hypersensitivity to ICP-022, nitrogen mustard benzoate, rituximab or any othercomponent of the applicable study drug.
3. Any mental or cognitive impairment that may limit their understanding of the informedconsent, their implementation and their compliance with the study.
4. Pregnant and lactating women, or subjects of childbearing age who do not want to usecontraception within 180 days from the end of the study period to the end of the studyperiod.
5. Conditions in which a potentially life-threatening illness or severe organ dysfunctionis not considered appropriate by the investigator. Note: Other protocol defined Inclusion/Exclusion criteria may apply.